Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been accepted for presentation at the European League Against Rheumatism (“EULAR”) 2018 Annual Meeting being held June 13-16, 2018 in Amsterdam, Netherlands. Read more >>